SG11202008017UA - Amanitin antibody conjugate - Google Patents
Amanitin antibody conjugateInfo
- Publication number
- SG11202008017UA SG11202008017UA SG11202008017UA SG11202008017UA SG11202008017UA SG 11202008017U A SG11202008017U A SG 11202008017UA SG 11202008017U A SG11202008017U A SG 11202008017UA SG 11202008017U A SG11202008017U A SG 11202008017UA SG 11202008017U A SG11202008017U A SG 11202008017UA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody conjugate
- amanitin antibody
- amanitin
- conjugate
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710804207 | 2017-09-08 | ||
PCT/CN2018/104712 WO2019047941A1 (zh) | 2017-09-08 | 2018-09-08 | 鹅膏毒肽类抗体偶联物 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202008017UA true SG11202008017UA (en) | 2020-09-29 |
Family
ID=65633573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202008017UA SG11202008017UA (en) | 2017-09-08 | 2018-09-08 | Amanitin antibody conjugate |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210113707A1 (ja) |
EP (1) | EP3735987A4 (ja) |
JP (1) | JP7296396B2 (ja) |
CN (1) | CN109464654B (ja) |
AU (1) | AU2018329066B2 (ja) |
CA (1) | CA3095211A1 (ja) |
SG (1) | SG11202008017UA (ja) |
WO (1) | WO2019047941A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022538692A (ja) * | 2019-07-05 | 2022-09-05 | プーレ バイオオーガニクス エスアイエー | α-アマニチン及びその誘導体の合成 |
EP3792250A1 (en) * | 2019-09-13 | 2021-03-17 | Pure Bioorganics SIA | Synthesis of alpha-amanitin and its derivatives |
EP4077353A1 (en) * | 2019-12-16 | 2022-10-26 | Heidelberg Pharma Research GmbH | Synthesis of amanin and its derivatives |
US20230220001A1 (en) * | 2020-06-09 | 2023-07-13 | Heidelberg Pharma Research Gmbh | Method for synthesis of thioether-containing peptides |
US20240082416A1 (en) * | 2020-12-08 | 2024-03-14 | The University Of British Columbia | Amatoxin analogs and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2436398B1 (en) * | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
EP2497499A1 (en) * | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
EP2684865A1 (en) * | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
WO2014043403A1 (en) * | 2012-09-12 | 2014-03-20 | Agensys, Inc. | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
WO2014107024A1 (ko) * | 2013-01-03 | 2014-07-10 | 셀트리온 | 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물 |
US20160220687A1 (en) * | 2015-02-02 | 2016-08-04 | National Guard Health Affairs | Metalloproteinase-cleavable alpha-amanitin-dendrimer conjugates and method of treating cancer |
CN107636016B (zh) * | 2015-03-09 | 2022-02-11 | 海德堡医药有限责任公司 | 鹅膏毒素-抗体轭合物 |
IL303455A (en) * | 2016-06-17 | 2023-08-01 | Crispr Therapeutics Ag | Compositions and methods for depleting CD117 plus cells |
-
2018
- 2018-09-08 AU AU2018329066A patent/AU2018329066B2/en active Active
- 2018-09-08 EP EP18852932.5A patent/EP3735987A4/en active Pending
- 2018-09-08 JP JP2020552290A patent/JP7296396B2/ja active Active
- 2018-09-08 WO PCT/CN2018/104712 patent/WO2019047941A1/zh unknown
- 2018-09-08 CA CA3095211A patent/CA3095211A1/en active Pending
- 2018-09-08 SG SG11202008017UA patent/SG11202008017UA/en unknown
- 2018-09-08 US US16/970,597 patent/US20210113707A1/en not_active Abandoned
- 2018-09-08 CN CN201811046475.9A patent/CN109464654B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CA3095211A1 (en) | 2019-03-14 |
AU2018329066B2 (en) | 2022-02-17 |
WO2019047941A1 (zh) | 2019-03-14 |
CN109464654A (zh) | 2019-03-15 |
CN109464654B (zh) | 2021-11-12 |
EP3735987A4 (en) | 2021-12-08 |
US20210113707A1 (en) | 2021-04-22 |
JP7296396B2 (ja) | 2023-06-22 |
EP3735987A1 (en) | 2020-11-11 |
JP2021518847A (ja) | 2021-08-05 |
AU2018329066A1 (en) | 2020-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201904269B (en) | Pyrrolobenzodiazepine-antibody conjugates | |
IL267797A (en) | Anti-gpc3 antibody | |
SG10201913942SA (en) | Amanitin conjugates | |
PT3606954T (pt) | Anticorpos anti-lag3 | |
IL290457A (en) | Antibodies and their conjugates | |
LT3544636T (lt) | Pirolobenzodiazepino-antikūno konjugatai | |
GB201702031D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
SG11202008017UA (en) | Amanitin antibody conjugate | |
DK3684416T3 (da) | Psma-målrettede amanitinkonjugater | |
GB201614162D0 (en) | Antibodies, uses thereof and conjugates thereof | |
IL273529A (en) | Anti-PACAP antibody | |
ZA201907673B (en) | Bone-targeting antibodies | |
ZA202003542B (en) | Anti-alpha-synuclein antibodies | |
SG11202008284XA (en) | Non-natural amatoxin-type antibody conjugate | |
AU2017380099B2 (en) | Amanitin antibody conjugates | |
GB201721290D0 (en) | Conjugates | |
GB201719906D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201719391D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201719393D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201719398D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201706466D0 (en) | pyrrolobenzodiazepine-peptide conjugates | |
GB201709592D0 (en) | Antibody | |
GB201702029D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201708105D0 (en) | Antibodies, uses thereof and conjugates thereof | |
GB201703071D0 (en) | Antibodies |